多替阿巴拉米片怎么用？

It is a compound preparation. Each tablet contains 50 mg of dolutegravir sodium (calculated as dolutegravir), 600 mg of abacavir sulfate (calculated as abacavir) and 300 mg of lamivudine. It is suitable for the treatment of adults and adolescents over 12 years old (with a weight of at least 40kg) infected with human immunodeficiency virus (HIV). Among them, dolutegravir can inhibit HIV integrase by binding to the active site of integrase and blocking the strand transfer step of reverse transcription deoxyribonucleic acid (DNA) integration (a key step in the HIV replication cycle). 

Dolutegra tablets should be taken under the guidance of a physician with experience in HIV infection. Dosage: Adults and Adolescents (weighing at least 40 kg): For adults and adolescents, the recommended dose of Dolutegra is one tablet, once daily. Adults or adolescents whose body weight is less than 40 kg should not be given dolutea as dolutea is a fixed-dose tablet and cannot be reduced. Dolutegravir is a fixed-dose tablet and should not be used in patients who require dose adjustments. If one of the active ingredients needs to be discontinued or a dose adjustment is required, separate formulations of dolutegravir, abacavir, or lamivudine may be used. In these cases, physicians should refer to the respective product information for these medicines. Missed dose: If the patient misses a dose of Docetaxel, and there are more than 4 hours before the next dose, Docetaxel should be taken as soon as possible. If the next dose is less than 4 hours away, patients should not take the missed dose and simply resume their usual dosing schedule. Geriatric patients: There are limited data on the use of dolutegravir, abacavir, and lamivudine in patients 65 years and older, and there is no evidence that older patients require different doses than younger adult patients. Taking into account age-related changes, such as decreased renal function and changes in hematological parameters, special caution is recommended when administering the drug in this age group. Renal damage: Patients with creatinine clearance less than 50 mL/min are not recommended to take doptabalamid tablets. Hepatic Impairment: Abacavir is primarily metabolized by the liver. There are no clinical data in patients with moderate or severe hepatic impairment; therefore, the use of dolutea is not recommended unless deemed necessary. For patients with mild hepatic impairment (Child-Pugh score 5-6), close monitoring is required, including monitoring of abacavir plasma levels if feasible. Pediatric Population: The safety and effectiveness of dolutea paramilk tablets in children under 12 years of age have not been established. Method of administration: Orally, with or without food.